approval · primary record
EMPAGLIFLOZIN
3 approval events · latest 2026-09-17
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-09-17 |
| Approval events | 3 |
| Brand | EMPAGLIFLOZIN |
| Sponsor | RIDHISIDHI, PLLC |
| Route | Not stated |
Approval history
3 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-09-17 | FDA | NDA | EMPAGLIFLOZIN | RIDHISIDHI, PLLC | — |
| 2026-08-11 | FDA | NDA | SYNJARDY | BOEHRINGER INGELHEIM | ORAL |
| 2025-10-24 | FDA | NDA | JARDIANCE | BOEHRINGER INGELHEIM | ORAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:29:37.276Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:empagliflozin
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Empagliflozin · compound